【摘要】 <正> 甲氰咪胍（Cimetidine）系组织胺H₂受体拮抗剂,1974年以来,国外用以治疗溃疡病,认为优于其它抗酸剂及抗胆碱能药物。1979年7月起,我院临床试用天津医药工业更多还原

【Abstract】 The effect of cimetidine made in China in peptic ulcer disease was assessed in controlled trial. 40 patients were treated with cimetidine and 9 patients with placebo. These 49 patients were endoscopically proved to be duodenal ulcer, Pyloric canal ulcer and gastric ulcer in the lesser curature. Only ulcer craters beloging to grade 4 of Binder’s Criteria wese studied. These patients did not have any cardiovascular, renal, hepatic or other disease.Patients were classfied into inpatient and outpatient groups of equal number, with about similar age and sex distribution. Duration of disease of both groups was also about the same. The dosage of the drug was 200mg taken orally after meal, three times daily with an additional dose of 400 mg at bed time. The gastric acid secretion of some patients was determined before and after treatment, and was found to show no significant change. After 4 weeks of treatment, the ulcer healing rate for the cimetidine group was 72.5%. There was not a single case in the placebo group showing complete healing. With large gastric ulcers in three patients greatly reduced in size after 4 weeks of treatment, the operative treatment originally plained was avoided. During the course of treatment few side effects were observed, patients tolerated the drug well. In a few patients diarrhoea was noted. Patients can be treated in the outpatient department. For short-term use the drug seems to be quite safe. The side effect and ulcer recurrence rate for long-term treatment, however, require further investigation.更多还原